



Announcement Summary

Entity name

PHARMAXIS LTD

Date of this announcement

Monday October 17, 2022

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
PXSAAS	PERFORMANCE RIGHTS	10,853,000	17/10/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

PHARMAXIS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

75082811630

1.3 ASX issuer code

PXS

1.4 The announcement is

New announcement

1.5 Date of this announcement

17/10/2022



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

PXSAAS : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

17/10/2022

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
David McGarvey	Same	1,376,000
Wolfgang Jarolimek	Same	1,322,000
Kristen Morgan	Same	867,000

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Grant Price: Nil
 2. Exercise Price: Nil
 3. Expiry: 30/6/32
 4. Each Right entitles the holder to receive one fully paid ordinary share in PXS.
 5. Vesting: 50% of will vest at 30/6/24 and 30/6/25, provided that the holder is an employee.
 6. Until 30/6/25, any shares acquired upon exercise of Rights may not be traded
 7. Any shares acquired upon exercise of Rights by Senior Executive Officers may only be traded with prior approval of the Board.
 The Performance Rights are granted pursuant to, and subject to, the terms and conditions of the Pharmaxis Performance Rights Plan - refer to the summary in the following document
<https://www.pharmaxis.com.au/assets/Documents/pdf/02021/ASX/2021-10-01-PXS-2021-AGM-Notice-of-Meeting.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Annual grant of performance rights to 28 senior managers and key staff (excluding the chief executive officer)



Issue details

Number of +securities

10,853,000

Part 4 - +Securities on issue

**Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)**

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
PXS : ORDINARY FULLY PAID	549,139,613

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
PXSAAP : OPTION EXPIRING 06-JUN-2023 EX NIL PRICE	66,500
PXSAAS : PERFORMANCE RIGHTS	29,292,550



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13